Dyslipidemia - Articles and news items

EC approves LDL cholesterol treatment Praluent

Industry news / 28 September 2015 / Victoria White

Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy…

Amgen to acquire biotechnology company Dezima

Industry news / 17 September 2015 / Victoria White

Under the terms of the acquisition agreement, Amgen will pay $300 million in cash at closing and up to $1.25 billion in additional payments…

EC approves Amgen’s cholesterol-lowering medication Repatha

Industry news / 21 July 2015 / Victoria White

The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction…

Results from Phase 2b study of CETP inhibitor TA-8995 published

Industry news / 3 June 2015 / Victoria White

Dezima Pharma has announced the publication of the phase 2b TULIP study results with its CETP inhibitor, TA-8995, in patients with mild dyslipidaemia…

Amgen receives positive CHMP opinion for use of Repatha for the treatment of high cholesterol

Industry news / 22 May 2015 / Victoria White

The CHMP has adopted a positive opinion for the marketing authorisation of Amgen’s Repatha for use in certain patients with high cholesterol…

Dyslipidemia treatment market value will approach $38 billion by 2023

Industry news / 20 May 2015 / Victoria White

The global treatment market for dyslipidemia will more than double from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, according to GlobalData…


Amgen presents long-term data showing efficacy and safety of investigational cholesterol-lowering medication evolocumab across lipid And LDL-C levels

Industry news / 19 November 2014 / Amgen

Additional data analysis showed every two week and monthly dosing regimens of evolocumab were clinically equivalent…


Amgen announces positive top-line results from Phase 3 YUKAWA-2 trial of evolocumab

Industry news / 28 August 2014 / Amgen

…in combination with statins in Japanese patients with high cardiovascular risk and high cholesterol.


New blockbuster drugs to more than triple acute coronary syndrome treatment market value by 2023

Industry news / 29 July 2014 / GlobalData

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome treatment market to more than triple in value…


Amgen announces positive top-line results from Phase 3 LAPLACE-2 trial of Evolocumab (AMG 145) in combination with statins in patients with high cholesterol

Industry news / 28 January 2014 / Amgen

Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints…


AstraZeneca to acquire Omthera Pharmaceuticals

Industry news / 28 May 2013 / AstraZeneca

AstraZeneca announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals…

Merck logo

Merck provides update on next steps for TREDAPTIVE™ (extended-release niacin/laropiprant)

Industry news, News / 11 January 2013 / Merck

Merck is taking steps to suspend the availability of TREDAPTIVE™ tablets worldwide…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...